Cargando…
Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis
In recent years, nerve growth factor (NGF) and the NGF receptor have become potential therapeutic targets in the treatment of acute and chronic pain states. NGF is a neurotrophin involved in regulating the function of sensory and sympathetic neurons during development. Numerous pain states have been...
Autores principales: | Patel, Mona K., Kaye, Alan D., Urman, Richard D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5885425/ https://www.ncbi.nlm.nih.gov/pubmed/29643634 http://dx.doi.org/10.4103/joacp.JOACP_389_15 |
Ejemplares similares
-
Response to: “Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis”
por: Tive, Leslie A., et al.
Publicado: (2018) -
Tanezumab: a selective humanized mAb for chronic lower back pain
por: Webb, Michael P, et al.
Publicado: (2018) -
Clinical Outcomes of Tanezumab With Different Dosages for Patient With Osteoarthritis: Network Meta-Analysis
por: Hu, Rui, et al.
Publicado: (2021) -
Tanezumab: Finally a Monoclonal Antibody for Pain Relief
por: Nair, Abhijit S
Publicado: (2018) -
Prediction of relative change in free nerve growth factor following subcutaneous administration of tanezumab, a novel monoclonal antibody to nerve growth factor
por: Shoji, Satoshi, et al.
Publicado: (2023)